Physicians' Academy for Cardiovascular Education

GLP-1 analogue in T2DM leads to amylase and lipase elevations but not acute pancreatitis

May 18, 2017 - Steinberg WM, et al. - Diabetes Care. 2017

In the LEADER study, numerically fewer events of acute pancreatitis were observed with liraglutide compared with placebo, but liraglutide did increased serum amylase and lipase levels.

Long term GLP-1 agonist treatment provides health benefits for prediabetics

Mar. 2, 2017 - le Roux CW, et al. - The Lancet 2017

Liraglutide reduced the risk of T2DM in overweight or obese individuals with prediabetes, and led to greater weight loss, improvements in glycaemic control and CV risk factors, compared with placebo.

GLP-1 agonist lowers CV biomarkers in high-risk T2DM patients

Jan. 25, 2017 - von Scholten BJ, et al. - Diabetes Obes Metab. 2017

In T2DM patients with albuminuria, liraglutide treatment associates with reductions in circulating levels of CV risk biomarkers.

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents

Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.

Liraglutide benefits subjects with metabolic syndrome

Dec. 8, 2016 - Rizzo M, et al, Cardiovasc. Diabetol, 2016

Liraglutide improved waist circumference, glucose parameters, plasma lipids and carotid intima media thickness in individuals with metabolic syndrome during an 18-month follow-up.

No improvement of systolic function with GLP-1 analogue in chronic HF patients with diabetes

Nov. 2, 2016 - Jorsal A, et al, Eur J Heart Fail, 2016

In HF patients with reduced LVEF and DM, no difference with regard to changes in LVEF was observed between the liraglutide and the placebo group. Liraglutide-treated patients did show more cardiac complications.

GLP1 analogue with extended half-life is non-inferior to placebo

Sep. 21, 2016 - Marso SP, et al, NEJM, 2016

Semaglutide was related to a significant lower risk of the primary composite outcome death from CV causes, nonfatal MI or nonfatal stroke as compared to placebo. 

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.

Current treatment of Diabetes in Heart Failure

May 21, 2016

The number of acute and chronic HF patients with diabetes (DM) increased tremendously over the last decade. The prevalence of DM in these patients now ranges between 13 and 47% and is even higher in HF patients with preserved ejection fraction (25-33%). Both diseases are deleterious, and prognosis is even worse when the two co-exist. ‘Diabetes and heart failure are fatal twins’, states professor Voors.

Increased acute CV risk 1 hour after moderate and heavy alcohol consumption

Mar. 8, 2016 - Mostofsky E et al., Circulation 2016

Moderate alcohol consumption was associated with a higher CV risk in the hour after alcohol intake, and a lower CV risk after 24 hours, while heavy drinking yields continuous CV risk.

GLP-1 analogue reduces the risk of major adverse cardiovascular events in type 2 diabetes

Mar. 7, 2016 - news

Liraglutide demonstrated superiority in reducing the primary endpoint of reducing CV death, non-fatal MI or non-fatal stroke, in T2DM patients at high CV risk in the LEADER trial.

Positive results from phase 2 trial with oral GLP-1 analogue

Feb. 23, 2015 - news

This phase 2 trial showed significant reductions in HbA1c with the long-acting GLP-1 analogue semaglutide in type 2 diabetes.